Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jul-Aug;18(4):592-3.
doi: 10.4103/1008-682X.172821.

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer

Jeanny B Aragon-Ching  1
Affiliations
Comment

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer

Jeanny B Aragon-Ching. Asian J Androl. 2016 Jul-Aug.

Abstract

The TOPARP study showed the beneficial utility of olaparib in a heavily pretreated population of metastatic castration-resistant prostate cancer who were biomarker-positive for aberrations in DNA repair gene. A higher response rate to olaparib of 88% (14 out of 16 patients), time to radiographic progression as well as overall survival, was seen in patients who were biomarker-positive compared to those who were not. This study showed a promising way of targeting prostate cancer with an enriched population of patients who harbor these deleterious genes. This paves the way for offering new therapeutic opportunities for men who have otherwise few remaining options.

Trial registration: ClinicalTrials.gov NCT02438007.

PubMed Disclaimer

Comment on

  • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. Mateo J, et al. N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859. N Engl J Med. 2015. PMID: 26510020 Free PMC article. Clinical Trial.

References

    1. FDA Approves Lynparza to Treat Advanced Ovarian Cancer. [Last accessed on 2015 Nov 14]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm .
    1. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708. - PMC - PubMed
    1. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38. - PMC - PubMed
    1. NCT02438007. A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV) [Last accessed on 2015 Nov 14]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02438007?term=ARMOR3 an... .
    1. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431–8. - PubMed

Substances

Associated data